[go: up one dir, main page]

AU2018448903A8 - Antibodies recognizing tau - Google Patents

Antibodies recognizing tau Download PDF

Info

Publication number
AU2018448903A8
AU2018448903A8 AU2018448903A AU2018448903A AU2018448903A8 AU 2018448903 A8 AU2018448903 A8 AU 2018448903A8 AU 2018448903 A AU2018448903 A AU 2018448903A AU 2018448903 A AU2018448903 A AU 2018448903A AU 2018448903 A8 AU2018448903 A8 AU 2018448903A8
Authority
AU
Australia
Prior art keywords
antibodies recognizing
tau
recognizing tau
antibodies
specifically bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2018448903A
Other versions
AU2018448903A1 (en
Inventor
Svetlana Alexander
Robin Barbour
Philip James Dolan Iii
Yue Liu
Tarlochan S. Nijjar
Mark E. RENZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of AU2018448903A1 publication Critical patent/AU2018448903A1/en
Publication of AU2018448903A8 publication Critical patent/AU2018448903A8/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
AU2018448903A 2018-11-08 2018-11-08 Antibodies recognizing tau Pending AU2018448903A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/059895 WO2020096608A1 (en) 2018-11-08 2018-11-08 Antibodies recognizing tau

Publications (2)

Publication Number Publication Date
AU2018448903A1 AU2018448903A1 (en) 2021-05-20
AU2018448903A8 true AU2018448903A8 (en) 2021-05-27

Family

ID=70611420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018448903A Pending AU2018448903A1 (en) 2018-11-08 2018-11-08 Antibodies recognizing tau

Country Status (4)

Country Link
AU (1) AU2018448903A1 (en)
CA (1) CA3118818A1 (en)
CU (1) CU20210039A7 (en)
WO (1) WO2020096608A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20152004A1 (en) 2013-03-13 2016-02-07 Prothena Biosciences Ltd IMMUNOTHERAPY TAU
WO2017191561A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CU24636B1 (en) 2017-05-02 2022-12-12 Prothena Biosciences Ltd ANTIBODIES RECOGNIZING TAU IN RESIDUES 257-271 OR 320-334 OF SEQ ID NO: 1
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
IL305161A (en) * 2021-02-14 2023-10-01 Prothena Biosciences Ltd Methods of using antibodies recognizing tau

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028777A2 (en) * 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
CA3022515A1 (en) * 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau

Also Published As

Publication number Publication date
WO2020096608A1 (en) 2020-05-14
CA3118818A1 (en) 2020-05-14
CU20210039A7 (en) 2021-12-08
AU2018448903A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
PH12021551048A1 (en) Antibodies recognizing tau
ZA202205817B (en) Antibodies recognizing tau
WO2018204546A3 (en) Antibodies recognizing tau
PH12018502054A1 (en) Antibodies recognizing tau
MY197413A (en) Antibodies recognizing tau
AU2018448903A8 (en) Antibodies recognizing tau
IL277072A (en) Anti-claudin 18.2 antibodies
EP3872093A4 (en) Anti-cldn18.2 antibody and uses thereof
EP3921343A4 (en) Antibodies recognizing tau
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
WO2014165271A3 (en) Tau immunotherapy
WO2020127377A9 (en) Bifunctional anti-pd-1/il-7 molecule
MX2021013417A (en) Clec12a-binding polypeptides and uses thereof.
WO2017075173A3 (en) Anti-factor d antibodies and conjugates
EP4083211A4 (en) Anti-cdcp1 antibody
WO2018046997A3 (en) Synthetic antibodies against vegf and their uses
AU2019361253A1 (en) Anti-synuclein antibodies
WO2019133902A3 (en) Antibodies and assays for ccl14
MX2020010092A (en) C-terminal antibody variants.
WO2023122766A3 (en) Antibodies recognizing sortilin
EP3862366A4 (en) Cancer-stem-cell-specific antibody
EP3858994A4 (en) Antibody composition
EP3816289A4 (en) Novel anti-pad2 antibody
EP3766898A4 (en) Cadm1 v9-recognizing antibody
MX2021010517A (en) Antibodies recognizing tau.

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 20 , PAGE(S) 4322 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PROTHENA BIOSCIENCES LIMITED, APPLICATION NO. 2018448903, UNDER INID (72) ADD CO-INVENTOR NIJJAR, TARLOCHAN S.